Log In
TZOO
$8.5
(0%)
FLWS
$9.27
(1.31%)
ACCO
$4.92
(1.55%)
AUXXF
$0.12
(0%)
ARLP
$21.51
(0.05%)
ALVOF
$3.51
(0.41%)
AUIAF
$0.14
(0%)
BSET
$13.47
(0%)
BXRX
$0
(0%)
BBGI
$0.7
(0%)
BSGM
$1.3
(0%)
BLBX
$2.66
(0%)
BOWL
$11.7
(1.39%)
COCP
$1.52
(0.66%)
CDRO
$6.74
(0%)
LODE
$0.32
(0.82%)
CMTL
$1.83
(-1.96%)
CXW
$15.07
(0.67%)
LCE:CA
$0.7
(0%)
CMLS
$2.74
(-0.72%)
DEFN:CA
$0.22
(2.33%)
DTGI
$0.03
(0%)
DRCT
$6.23
(1.8%)
DLHC
$10.82
(1.41%)
SSP
$3.73
(1.22%)
EGLE
$0
(0%)
ELMGF
$0.19
(0.16%)
UUUU
$5.33
(-0.56%)
GAME
$1.56
(-1.27%)
EVC
$2.12
(0.95%)
ESK:CA
$0.36
(-1.35%)
GMBL
$0.65
(0%)
EDRY
$20.67
(1.17%)
ESEA
$34.16
(0.56%)
GNK
$21.32
(0.42%)
GEVO
$0.61
(1.94%)
GRIN
$13.6
(-0.15%)
GTN
$5.83
(0.95%)
HHS
$6.98
(0%)
INDO
$4.3
(3.86%)
IPOOF
$1.82
(0.55%)
KNDI
$2.69
(0%)
MSGM
$2.39
(-5.16%)
PANL
$7
(1.16%)
PXS
$4.58
(2.46%)
QMCI
$0.22
(0%)
SALM
$0.36
(14.25%)
SHIP
$9.58
(1.38%)
TSQ
$12.16
(0.25%)
TZOO
$8.5
(0%)
FLWS
$9.27
(1.31%)

channelchek-in

‌
4/26/2024

Incyte Shells Out $750M for Escient’s Immunology Assets

In a move that further solidifies its position in the inflammatory disease space, Incyte Corporation has agreed to acquire Escient Pharmaceuticals for $750 million. The deal, announced on Tuesday, will add two promising immunology and inflammation candidates to Incyte’s pipeline, complementing its existing dermatology portfolio.

0
3 min read
  • ‌
    Billionaire Leon Cooperman Sounds the Alarm on Looming Financial Crisis

    Billionaire Leon Cooperman Sounds the Alarm on Looming Financial Crisis

    In a characteristically blunt assessment, billionaire investor Leon Cooperman pa...

    3 min read

  • Noble Capital Markets Emerging Growth Virtual Healthcare Conference Presentation Replays

    9 min read

  • Receive FREE Research, News, and Video Updates in your inbox.

  • The New York Stock Exchange’s Bold Proposal for 24/7 Trading: Risks and Opportunities

    4 min read
View all

News

4/26/2024

Incyte Shells Out $750M for Escient’s Immunology Assets

3 min read
‌
Incyte Shells Out $750M for Escient’s Immunology Assets
4/26/2024

Release – ACCO Brands Corporation Declares Quarterly Dividend

2 min read
‌
Release – ACCO Brands Corporation Declares Quarterly Dividend
4/26/2024

Release – Ocugen To Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting

6 min read
‌
Release – Ocugen To Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting
4/25/2024

Release – Entravision Schedules First Quarter 2024 Earnings Release and Conference Call

3 min read
‌
Release – Entravision Schedules First Quarter 2024 Earnings Release and Conference Call
View all

Research Reports

Travelzoo (TZOO) – An Improved Balance Sheet; Stable OutlookT(MustGrow Biologics Corp. (MGROF) – Releases Fiscal Year 2023 ResultsMBC(Comstock Inc. (LODE) – Comstock Fuels Gains Commercial MomentumCI(Direct Digital Holdings (DRCT) – Marcum Gives A Bad ImpressionDDH(
View all

Video Content

  • ‌
    DarioHealth Corp.

    DarioHealth Corp.

    Conference Presentation
    4/18/2024
  • ‌
    Cadrenal Therapeutics Inc.

    Cadrenal Therapeutics Inc.

    Conference Presentation
    4/18/2024
  • ‌
    Kiora Pharmaceuticals Inc.

    Kiora Pharmaceuticals Inc.

    Conference Presentation
    4/18/2024
  • ‌
    Anavex Life Sciences Corp.

    Anavex Life Sciences Corp.

    Conference Presentation
    4/18/2024
    • View all

    Movers

    Symbol
    Change
    ZVSA
    826.75%
    BDRX
    83.49%
    FCUV
    75.31%
    PEGY
    62.91%
    CCBI:CA
    49.44%
    View all
    Log In
    © 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.
    Log In